Gene editing may provide hope for the treatment of Fragile X, the leading genetic cause of autism.
Fragile X syndrome patients with prematuration had a much earlier onset of neurological problems, including earlier symptoms of neurodegeneration. They also experienced emotional processing problems. Some of the most common emotional processing disorders reported were mood regulation, anxiety, and psychosis.
A new mouse study reveals a drug compound is effective at treating and potentially reversing symptoms of Fragile x syndrome.
Study identifies a short gene segment crucial for brain development and information processing. The absence of the gene segment induces altered social behaviors, learning difficulties, and memory deficits, which are hallmarks of a subset of ASD.
Stem cell study reveals a genetic defect associated with fragile X syndrome delays the production of neurons during a critical stage of embryonic development.
Researchers report alterations in RNA editing play a vital role in autism spectrum disorder.
A new study reveals how neurogranin and FMRP help encode memories of new places.
Researchers have derived purkinje cells from patients with TSC, a genetic syndrome that includes some ASD-like symptoms. The cells, researchers say, have several characteristics that could help explain how ASD develops at the molecular level.
According to researchers, treatment that target chromatin remodelers may provide new avenues of treatment for Fragile X Syndrome and other autism spectrum disorders.
A pre-clinical mouse study may provide an exciting new step toward developing new treatment approaches for Fragile X.
A new study reveals the role two Pumilio genes, PUM1, and PUM2, play in the creation of new neurons in the dentate gyrus.
A groundbreaking new study that looked at brain samples from humans with Fragile X reports the window for treatment remains open well into maturity.
